From isolation to exploration
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Search results
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
A new approach to treating inherited sight loss
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
This October, join Retina UK on Halloween weekend (28 and 29 October 2023) and face your fears by taking on a Halloween skydive at various airfields around the UK.
This November, join Retina UK on Bonfire weekend (4 and 5 November 2023) and face your fears by taking on a Bonfire skydive at various airfields around the UK.
Various dates and locations available. Skydiving is an exhilarating experience, and you can do this while supporting our cause.
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.